Skip to main content
Top
Published in: Internal and Emergency Medicine 4/2013

01-06-2013 | IM - ORIGINAL

Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels?

Authors: Lucia Carulli, Stefano Ballestri, Amedeo Lonardo, Francesca Lami, Enrico Violi, Luisa Losi, Lisa Bonilauri, Anna Maria Verrone, Maria Rosaria Odoardi, Federica Scaglioni, Marco Bertolotti, Paola Loria

Published in: Internal and Emergency Medicine | Issue 4/2013

Login to get access

Abstract

Hypothyroidism is associated with the risk of development of the metabolic syndrome (MS) and hypercholesterolemia. Direct evidence that hypothyroidism might be associated with advanced chronic liver disease via nonalcoholic steatohepatitis (NASH) is limited. We studied the relationship between thyroid hormones, thyroid stimulating hormone (TSH), cholesterol, and NASH. In consecutive euthyroid patients with biopsy-proven nonalcoholic fatty liver disease, TSH and thyroid hormone (FT3 and FT4) concentrations were compared in 25 patients with steatosis and 44 non-cirrhotic NASH patients featuring concurrent ballooning, lobular inflammation and steatosis. The MS was diagnosed according to ATP III criteria. A meta-analysis of previously published studies was performed to evaluate whether NASH, compared to simple steatosis, is associated with lower cholesterol levels. At univariate analysis, compared to those with steatosis, patients with NASH have a wider waist, elevated levels of BMI, ALT, AST, fasting insulin, HOMA-IR, ferritin, TSH and a lower serum cholesterol. At stepwise multivariable logistic regression analysis, the independent predictors of NASH are high HOMA and TSH and lower total cholesterol (Model 1); MS and high TSH (Model 2). At meta-analysis, serum total cholesterol levels are significantly lower in predominantly non-cirrhotic NASH than in simple steatosis. This study provides cross-sectional and meta-analytic evidence that, in euthyroid patients, high-though-normal TSH values are independently associated with NASH. Further work is needed to ascertain the role, if any, of lower cholesterol serum levels in assisting in the diagnosis of NASH.
Literature
1.
go back to reference Loria P, Carulli L, Bertolotti M, Lonardo A (2009) Endocrine and liver interaction: the role of endocrine pathways in NASH. Nat Rev Gastroenterol Hepatol 6:236–247PubMedCrossRef Loria P, Carulli L, Bertolotti M, Lonardo A (2009) Endocrine and liver interaction: the role of endocrine pathways in NASH. Nat Rev Gastroenterol Hepatol 6:236–247PubMedCrossRef
2.
go back to reference Vuppalanchi R, Chalasani N (2009) Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 49:306–317PubMedCrossRef Vuppalanchi R, Chalasani N (2009) Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 49:306–317PubMedCrossRef
4.
go back to reference Lin SY, Wang YY, Liu PH, Lai WA, Sheu WH (2005) Lower serum free thyroxine levels are associated with metabolic syndrome in a Chinese population. Metabolism 54:1524–1528PubMedCrossRef Lin SY, Wang YY, Liu PH, Lai WA, Sheu WH (2005) Lower serum free thyroxine levels are associated with metabolic syndrome in a Chinese population. Metabolism 54:1524–1528PubMedCrossRef
5.
go back to reference Baxter JD, Webb P (2009) Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov 8:308–320PubMedCrossRef Baxter JD, Webb P (2009) Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov 8:308–320PubMedCrossRef
6.
go back to reference George J, Liddle C (2008) Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets. Mol Pharm 5:49–59PubMedCrossRef George J, Liddle C (2008) Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets. Mol Pharm 5:49–59PubMedCrossRef
7.
go back to reference Arrese M (2009) Burning hepatic fat: therapeutic potential for liver-specific thyromimetics in the treatment of nonalcoholic fatty liver disease. Hepatology 49:348–351PubMedCrossRef Arrese M (2009) Burning hepatic fat: therapeutic potential for liver-specific thyromimetics in the treatment of nonalcoholic fatty liver disease. Hepatology 49:348–351PubMedCrossRef
8.
go back to reference Wartofsky L, Dickey RA (2005) The evidence for a narrower thyrotropin reference range is compelling. J Clin Endocrinol Metab 90:5483–5488PubMedCrossRef Wartofsky L, Dickey RA (2005) The evidence for a narrower thyrotropin reference range is compelling. J Clin Endocrinol Metab 90:5483–5488PubMedCrossRef
9.
go back to reference Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ (2004) Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 291:228–238PubMedCrossRef Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ (2004) Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 291:228–238PubMedCrossRef
10.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef
11.
go back to reference Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2002) American Diabetes Association: clinical practice recommendations. Diabetes Care 25:S1–147 Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2002) American Diabetes Association: clinical practice recommendations. Diabetes Care 25:S1–147
12.
go back to reference Mancia G, De Backer G, Dominiczak A et al (2007) 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28:1462–1536PubMed Mancia G, De Backer G, Dominiczak A et al (2007) 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28:1462–1536PubMed
13.
go back to reference National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421 National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421
14.
go back to reference Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F, American Heart Association; National Heart, Lung, and Blood Institute (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735–2752PubMedCrossRef Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F, American Heart Association; National Heart, Lung, and Blood Institute (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735–2752PubMedCrossRef
15.
go back to reference Brunt EM, Janney C, Di Bisceglie A et al (1999) Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94:2467–2474PubMedCrossRef Brunt EM, Janney C, Di Bisceglie A et al (1999) Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94:2467–2474PubMedCrossRef
16.
go back to reference Dixon JB, Bhathal PS, O’Brien PE (2001) Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121:91–100PubMedCrossRef Dixon JB, Bhathal PS, O’Brien PE (2001) Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121:91–100PubMedCrossRef
17.
go back to reference Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37:917–923PubMedCrossRef Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37:917–923PubMedCrossRef
18.
go back to reference Boza C, Riquelme A, Ibañez L, Duarte I, Norero E, Viviani P, Soza A, Fernandez JI, Raddatz A, Guzman S, Arrese M (2005) Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg 15:1148–1153PubMedCrossRef Boza C, Riquelme A, Ibañez L, Duarte I, Norero E, Viviani P, Soza A, Fernandez JI, Raddatz A, Guzman S, Arrese M (2005) Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg 15:1148–1153PubMedCrossRef
19.
go back to reference Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD, Goodman Z, Younossi ZM (2005) Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 15:310–315PubMedCrossRef Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD, Goodman Z, Younossi ZM (2005) Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 15:310–315PubMedCrossRef
20.
go back to reference Harnois F, Msika S, Sabaté JM, Mechler C, Jouet P, Barge J, Coffin B (2006) Prevalence and predictive factors of non-alcoholic steatohepatitis (NASH) in morbidly obese patients undergoing bariatric surgery. Obes Surg 16:183–188PubMedCrossRef Harnois F, Msika S, Sabaté JM, Mechler C, Jouet P, Barge J, Coffin B (2006) Prevalence and predictive factors of non-alcoholic steatohepatitis (NASH) in morbidly obese patients undergoing bariatric surgery. Obes Surg 16:183–188PubMedCrossRef
21.
go back to reference Abiru S, Migita K, Maeda Y, Daikoku M, Ito M, Ohata K, Nagaoka S, Matsumoto T, Takii Y, Kusumoto K, Nakamura M, Komori A, Yano K, Yatsuhashi H, Eguchi K, Ishibashi H (2006) Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int 26:39–45PubMedCrossRef Abiru S, Migita K, Maeda Y, Daikoku M, Ito M, Ohata K, Nagaoka S, Matsumoto T, Takii Y, Kusumoto K, Nakamura M, Komori A, Yano K, Yatsuhashi H, Eguchi K, Ishibashi H (2006) Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int 26:39–45PubMedCrossRef
22.
go back to reference Liang RJ, Wang HH, Lee WJ, Liew PL, Lin JT, Wu MS (2007) Diagnostic value of ultrasonographic examination for nonalcoholic steatohepatitis in morbidly obese patients undergoing laparoscopic bariatric surgery. Obes Surg 17:45–56PubMedCrossRef Liang RJ, Wang HH, Lee WJ, Liew PL, Lin JT, Wu MS (2007) Diagnostic value of ultrasonographic examination for nonalcoholic steatohepatitis in morbidly obese patients undergoing laparoscopic bariatric surgery. Obes Surg 17:45–56PubMedCrossRef
23.
go back to reference Park JW, Jeong G, Kim SJ, Kim MK, Park SM (2007) Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: comprehensive study of clinical and immunohistochemical findings in younger Asian patients. J Gastroenterol Hepatol 22:491–497PubMedCrossRef Park JW, Jeong G, Kim SJ, Kim MK, Park SM (2007) Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: comprehensive study of clinical and immunohistochemical findings in younger Asian patients. J Gastroenterol Hepatol 22:491–497PubMedCrossRef
24.
go back to reference Canbakan B, Senturk H, Tahan V, Hatemi I, Balci H, Toptas T, Sonsuz A, Velet M, Aydin S, Dirican A, Ozgulle S, Ozbay G (2007) Clinical, biochemical and histological correlations in a group of non-drinker subjects with non-alcoholic fatty liver disease. Acta Gastroenterol Belg 70:277–284PubMed Canbakan B, Senturk H, Tahan V, Hatemi I, Balci H, Toptas T, Sonsuz A, Velet M, Aydin S, Dirican A, Ozgulle S, Ozbay G (2007) Clinical, biochemical and histological correlations in a group of non-drinker subjects with non-alcoholic fatty liver disease. Acta Gastroenterol Belg 70:277–284PubMed
25.
go back to reference Chtioui H, Semela D, Ledermann M, Zimmermann A, Dufour JF (2007) Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis. Liver Int 27:764–771PubMedCrossRef Chtioui H, Semela D, Ledermann M, Zimmermann A, Dufour JF (2007) Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis. Liver Int 27:764–771PubMedCrossRef
26.
go back to reference García-Galiano D, Sánchez-Garrido MA, Espejo I, Montero JL, Costán G, Marchal T, Membrives A, Gallardo-Valverde JM, Muñoz-Castañeda JR, Arévalo E, De la Mata M, Muntané J (2007) IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. Obes Surg 17:493–503PubMedCrossRef García-Galiano D, Sánchez-Garrido MA, Espejo I, Montero JL, Costán G, Marchal T, Membrives A, Gallardo-Valverde JM, Muñoz-Castañeda JR, Arévalo E, De la Mata M, Muntané J (2007) IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. Obes Surg 17:493–503PubMedCrossRef
27.
go back to reference Yamamoto M, Iwasa M, Iwata K, Kaito M, Sugimoto R, Urawa N, Mifuji R, Konishi M, Kobayashi Y, Adachi Y (2007) Restriction of dietary calories, fat and iron improves non-alcoholic fatty liver disease. J Gastroenterol Hepatol 22:498–503PubMedCrossRef Yamamoto M, Iwasa M, Iwata K, Kaito M, Sugimoto R, Urawa N, Mifuji R, Konishi M, Kobayashi Y, Adachi Y (2007) Restriction of dietary calories, fat and iron improves non-alcoholic fatty liver disease. J Gastroenterol Hepatol 22:498–503PubMedCrossRef
28.
go back to reference Arvaniti VA, Thomopoulos KC, Tsamandas A, Makri M, Psyrogiannis A, Vafiadis G, Assimakopoulos SF, Labropoulou-Karatza C (2008) Serum adiponectin levels in different types of non alcoholic liver disease. Correlation with steatosis, necroinflammation and fibrosis. Acta Gastroenterol Belg. 71:355–360PubMed Arvaniti VA, Thomopoulos KC, Tsamandas A, Makri M, Psyrogiannis A, Vafiadis G, Assimakopoulos SF, Labropoulou-Karatza C (2008) Serum adiponectin levels in different types of non alcoholic liver disease. Correlation with steatosis, necroinflammation and fibrosis. Acta Gastroenterol Belg. 71:355–360PubMed
29.
go back to reference Ma H, Gomez V, Lu L, Yang X, Wu X, Xiao SY (2009) Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 24:233–237PubMedCrossRef Ma H, Gomez V, Lu L, Yang X, Wu X, Xiao SY (2009) Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 24:233–237PubMedCrossRef
30.
go back to reference Nannipieri M, Cecchetti F, Anselmino M, Mancini E, Marchetti G, Bonotti A, Baldi S, Solito B, Giannetti M, Pinchera A, Santini F, Ferrannini E (2009) Pattern of expression of adiponectin receptors in human liver and its relation to nonalcoholic steatohepatitis. Obes Surg 19:467–474PubMedCrossRef Nannipieri M, Cecchetti F, Anselmino M, Mancini E, Marchetti G, Bonotti A, Baldi S, Solito B, Giannetti M, Pinchera A, Santini F, Ferrannini E (2009) Pattern of expression of adiponectin receptors in human liver and its relation to nonalcoholic steatohepatitis. Obes Surg 19:467–474PubMedCrossRef
31.
go back to reference Sookoian S, Castaño G, Burgueño AL, Gianotti TF, Rosselli MS, Pirola CJ (2009) A diagnostic model to differentiate simple steatosis from nonalcoholic steatohepatitis based on the likelihood ratio form of Bayes theorem. Clin Biochem 42:624–629PubMedCrossRef Sookoian S, Castaño G, Burgueño AL, Gianotti TF, Rosselli MS, Pirola CJ (2009) A diagnostic model to differentiate simple steatosis from nonalcoholic steatohepatitis based on the likelihood ratio form of Bayes theorem. Clin Biochem 42:624–629PubMedCrossRef
32.
go back to reference Uzunlulu M, Yorulmaz E, Oguz A (2007) Prevalence of subclinical hypothyroidism in patients with metabolic syndrome. Endocr J 54:71–76PubMedCrossRef Uzunlulu M, Yorulmaz E, Oguz A (2007) Prevalence of subclinical hypothyroidism in patients with metabolic syndrome. Endocr J 54:71–76PubMedCrossRef
33.
go back to reference Shantha GP, Kumar AA, Jeyachandran V, Rajamanickam D, Rajkumar K, Salim S, Subramanian KK, Natesan S (2009) Association between primary hypothyroidism and metabolic syndrome and the role of C reactive protein: a cross-sectional study from South India. Thyroid Res 2:2PubMedCrossRef Shantha GP, Kumar AA, Jeyachandran V, Rajamanickam D, Rajkumar K, Salim S, Subramanian KK, Natesan S (2009) Association between primary hypothyroidism and metabolic syndrome and the role of C reactive protein: a cross-sectional study from South India. Thyroid Res 2:2PubMedCrossRef
34.
go back to reference Liangpunsakul S, Chalasani N (2003) Is hypothyroidism a risk factor for non-alcoholic steatohepatitis? J Clin Gastroenterol 37:340–343PubMedCrossRef Liangpunsakul S, Chalasani N (2003) Is hypothyroidism a risk factor for non-alcoholic steatohepatitis? J Clin Gastroenterol 37:340–343PubMedCrossRef
35.
go back to reference Reddy A, Dash C, Leerapun A, Mettler TA, Stadheim LM, Lazaridis KN et al (2007) Hypothyroidism: a possible risk factor for liver cancer in patients with no known underlying cause of liver disease. Clin Gastroenterol Hepatol 5:118–123PubMedCrossRef Reddy A, Dash C, Leerapun A, Mettler TA, Stadheim LM, Lazaridis KN et al (2007) Hypothyroidism: a possible risk factor for liver cancer in patients with no known underlying cause of liver disease. Clin Gastroenterol Hepatol 5:118–123PubMedCrossRef
36.
go back to reference Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, Curley SA, Spitz MR, Sherman SI, Abdalla EK, Davila M, Lozano RD, Hassan DM, Chan W, Brown TD, Abbruzzese JL (2009) Association between hypothyroidism and hepatocellular carcinoma: a case–control study in the United States. Hepatology 49:1563–1570PubMedCrossRef Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, Curley SA, Spitz MR, Sherman SI, Abdalla EK, Davila M, Lozano RD, Hassan DM, Chan W, Brown TD, Abbruzzese JL (2009) Association between hypothyroidism and hepatocellular carcinoma: a case–control study in the United States. Hepatology 49:1563–1570PubMedCrossRef
37.
go back to reference Reinher T (2010) Obesity and thyroid function. Mol Cell Endocrinol 316:165–171CrossRef Reinher T (2010) Obesity and thyroid function. Mol Cell Endocrinol 316:165–171CrossRef
38.
go back to reference Alberiche M, Boronat M, Saavedra P, Pérez N, Marrero D, López-Plasencia Y, Varillas VF, Ríos M, Nóvoa FJ (2009) Thyrotropin levels and their relationship with cardiovascular risk factors in the island of Gran Canaria, Spain. Implications of lowering the upper reference limit of thyrotropin stimulating hormone. J Endocrinol Invest 32:102–106PubMed Alberiche M, Boronat M, Saavedra P, Pérez N, Marrero D, López-Plasencia Y, Varillas VF, Ríos M, Nóvoa FJ (2009) Thyrotropin levels and their relationship with cardiovascular risk factors in the island of Gran Canaria, Spain. Implications of lowering the upper reference limit of thyrotropin stimulating hormone. J Endocrinol Invest 32:102–106PubMed
39.
go back to reference Park HT, Cho GJ, Ahn KH, Shin JH, Hong SC, Kim T, Hur JY, Kim YT, Lee KW, Kim SH (2009) Thyroid stimulating hormone is associated with metabolic syndrome in euthyroid postmenopausal women. Maturitas 62:301–305PubMedCrossRef Park HT, Cho GJ, Ahn KH, Shin JH, Hong SC, Kim T, Hur JY, Kim YT, Lee KW, Kim SH (2009) Thyroid stimulating hormone is associated with metabolic syndrome in euthyroid postmenopausal women. Maturitas 62:301–305PubMedCrossRef
40.
go back to reference Mason RL, Hunt HM, Hurxthal L (1930) Blood cholesterol values in hyperthyroidism and hypothyroidism: their significance. New Engl J Med 203:1273–1278CrossRef Mason RL, Hunt HM, Hurxthal L (1930) Blood cholesterol values in hyperthyroidism and hypothyroidism: their significance. New Engl J Med 203:1273–1278CrossRef
41.
go back to reference D’Arienzo A, Manguso F, Scaglione G, Vicinanza G, Bennato R, Mazzacca G (1998) Prognostic value of progressive decrease in serum cholesterol in predicting survival in Child-Pugh C viral cirrhosis. Scand J Gastroenterol 33:1213–1218PubMedCrossRef D’Arienzo A, Manguso F, Scaglione G, Vicinanza G, Bennato R, Mazzacca G (1998) Prognostic value of progressive decrease in serum cholesterol in predicting survival in Child-Pugh C viral cirrhosis. Scand J Gastroenterol 33:1213–1218PubMedCrossRef
42.
go back to reference Bookman ID, Pham J, Guindi M, Heathcote EJ (2006) Distinguishing nonalcoholic steatohepatitis from fatty liver: serum-free fatty acids, insulin resistance, and serum lipoproteins. Liver Int 26:566–571PubMedCrossRef Bookman ID, Pham J, Guindi M, Heathcote EJ (2006) Distinguishing nonalcoholic steatohepatitis from fatty liver: serum-free fatty acids, insulin resistance, and serum lipoproteins. Liver Int 26:566–571PubMedCrossRef
43.
go back to reference Tokushige K, Takakura M, Tsuchiya-Matsushita N, Taniai M, Hashimoto E, Shiratori K (2007) Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J Hepatol 46:1104–1110PubMedCrossRef Tokushige K, Takakura M, Tsuchiya-Matsushita N, Taniai M, Hashimoto E, Shiratori K (2007) Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J Hepatol 46:1104–1110PubMedCrossRef
Metadata
Title
Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels?
Authors
Lucia Carulli
Stefano Ballestri
Amedeo Lonardo
Francesca Lami
Enrico Violi
Luisa Losi
Lisa Bonilauri
Anna Maria Verrone
Maria Rosaria Odoardi
Federica Scaglioni
Marco Bertolotti
Paola Loria
Publication date
01-06-2013
Publisher
Springer Milan
Published in
Internal and Emergency Medicine / Issue 4/2013
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-011-0609-4

Other articles of this Issue 4/2013

Internal and Emergency Medicine 4/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.